Privat-Dozent Dr. Richard Musil

• EudraCT-Nummer 2005-004501-28: „Study to compare ziprasidone (Zeldox) versus Aripiprazole (Abilify) on cognitive functions and sleep quality in the treatment of schizophrenic patients“ (2005-2008; Sub-PI)
• D1441C00125: „A 24-week, international, multi-centre, open-label, flexible-dose, randomised, parallel-group, phase IV study to compare the effect on glucose metabolism of quetiapine, olanzapine and risperidone in the treatment of patients with schizophrenia“ (2005-2006; Sub-PI)
• EudraCT-Number: 2004-001302-27: „An 8-week exploratory, double-blind, placebo controlled, randomized trial: evaluation of the efficacy and safety of levetiracetam up to 3000 mg/day on neuroleptic-induced tardive dyskinesia in subjects with stable axis I psychiatric disorder“ (2006-2008; Sub-PI)
• F1D-MC-HGKA: „A double-blind randomized study comparing intramuscular olanzapine depot to oral olanzapine and low-dose intramuscular Olanzapine Depot in the maintenance therapy of patients with schizophrenia“ (2006-2008; Sub-PI)
• EudraCT Nummer: 2006-003475-13: “A sixteen-week, multi-centre, open-label study evaluating the safety, tolerability, and efficacy of switching from quetiapine to ziprasidone in subjects diagnosed with schizophrenia or schizoaffective disorder” (2006-2008; Sub-PI)
• SCoP99824: “A prospective, open-label, single arm, multinational, multi-centre, flexible dose, extension study of the SCoP 99824 with sertindole for patients suffering from schizophrenia“ (2007-2009; Sub-PI)
• Protocol No. 31-08-248, IND. No. 67,380: “A 52 week, multicenter, open-label study to evaluate the effectiveness of aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia” (2009; Sub-PI)
• RISSCH4091: „Postacute treatment of schizophrenic patients with risperidone long-acting injectable in outpatient departments of psychiatric hospitals“ (2008-2010; Sub-PI)
• RISSCH4023: „LaRA – Longterm tolerability in relapse prophylactic therapy with atypicals“ (2008-2010; Sub-PI)
• PERFlexS Ro76477SCH3017: „Post-Marketing Surveillance Study of paliperidone in an outpatinet setting“ (2009-2010; Sub-PI)
• D1444C00147: „A 12 week international, multicentre, open-label, non-comparative study to evaluate the feasability of switching any antipsychotic treatment to sustained-release quetiapine fumarate in patients with schizophrenia” (2009-2010; Sub-PI)
• SearchLyte WN25309, EudraCT Nummer: 2010-020467-21: „A Phase III, multi-center, randomized, 24 week, double-blind, parallel-group, placebocontrolled study to evaluate efficacy and safety of RO4917838 in stable patients with persistent, predominant negative symptoms of schizophrenia treated with antipsychotics followed by a 28 week, double-blind treatment period.“ (2010-2012; PI)
• SWITCH 01KG0910, EudraCT-Nummer 2009-012031-15: „The SWITCH-trial to evaluate the effectiveness of a medication switch versus continuation of antipsychotic treatment in patients with schizophrenia, who did not sufficiently respond after two weeks of treatment.“ (2009-2013; PI)
• ONLINE-TICS: „Randomized observer blind clinical trial to demonstrate the efficacy and safety of internet-delivered behavioral treatment for adults with tic disorders (ONLINE-TICS)” (2015-ongoing; PI)
• CANNA-TICS EudraCT-Nummer 2016-000564-42: “A randomized multi-centre double-blind placebo controlled trial to demonstrate the efficacy and safety of nabiximols in the treatment of adults with chronic tic disorders (CANNA-TICS)” (2016-ongoing; PI)
• THX-G18-001 EudraCT-Nummer: 2018-000014-38: „A Randomized, Double-Blind, Placebo Controlled Proof of Concept Study to Evaluate the Safety, Tolerability and Efficacy of Daily Oral THX-110 in Treating Adults with Tourette Syndrome (“ENTOURAGE”)” (2018-ongoing PI)
• ABX-1431 EudraCT-Nummer: 2018-000100-41: „A Randomized, Placebo-Controlled Study of ABX-1431 in Adult Patients with Tourette Syndrome or Chronic Motor Tic Disorder” (2018-2020 PI)
• EBS-101-CL-001 EudraCT-Nummer: 2019-000281-37: „A Multicenter, Placebo Controlled, Double-Blind, Randomized, Parallel Group Phase 2b Study to Evaluate the Efficacy and Safety of Ecopipam Tablets in Children and Adolescent Subjects with Tourette’s Syndrome” (2019-2022 PI)
• PSR DBS OCD: „Product Surveillance Registry – Neurological (“Registry”)” (2019-ongoing PI)
• Otsuka 331-201-00242 EudraCT-Nummer: 2019-002813-20: „A Multicenter, Randomized, Flexible-dose, Double-blind Trial of Brexpiprazole Versus Placebo for the Treatment of Adults With Borderline Personality Disorder” (2019-2020 PI)
• BI1402-0012 EudraCT-Nummer: 2020-000078-12: „A phase II randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of 4 oral doses of BI 1358894 once daily over 12 week treatment period in patients with borderline personality disorder” (2020-2023 PI)
• BI1402-0030 EudraCT-Nummer: 2021-003154-23: „A phase II, 8-week-treatment, multicenter, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy, tolerability and safety of orally administered BI 1358894 in patients with Post-Traumatic Stress Disorder” (2021-2024 PI)
• EBS-101-TD-301 EudraCT-Nummer: 2023-503494-00: „A Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Safety and Maintenance of Efficacy of Ecopipam in Children, Adolescents and Adults with Tourette’s Disorder” (2023-2025 PI)
• NOE-TTS-201: „A Double-Blind, Placebo-Controlled, Phase II/III, Multi-center, Twelve-week Prospective Study to Evaluate the Efficacy and Safety of Gemlapodect in Adult and Adolescent Patients with Tourette Syndrome” (2023-2026 PI)

1. Kunz JI, Zwick A, Boll JJ, Wolf J, Meinhardt J, Hüttner S, Grigo R, Musil R, Goerigk S, Jobst A, Padberg F, Reinhard MA. Changes of borderline symptoms, personality functioning, and dysfunctional personality traits after dialectical-behavioral therapy in borderline personality disorder.
   Eur Arch Psychiatry Clin Neurosci. 2026 May 8. Doi: 10.1007/s00406-026-02215-z.
   Impact factor (2024): 3,7

2. Kunz JI, Barton BB, Wolfrum N, Wolf J, Merz K, Musil R, Goerigk S, Jobst A, Bertsch K, Padberg F, Reinhard MA. Loneliness and Its Associations With Personality Functioning: Evidence From Longitudinal Inpatient Psychotherapy Programs in Germany.
   Ann N Y Acad Sci. 2026 Feb;1556(1):e70215. Doi: 10.1111/nyas.70215.
   Impact factor (2024): 4,8

3. Nierychlewski K, Paal M, Meinzer S, Musil R, Schwarz M. Optimizing therapeutic drug monitoring of mirtazapine – applying therapeutic reference range, concentration-dose ratio/dose-related concentration, and metabolic ratio in a naturalistic setting.
   Eur J Clin Pharmacol. 2025 Nov;81(11):1677-1687. Doi: 10.1007/s0028-025-03908-6.
   Impact factor (2024): 2,7

4. Schoenweger P, Eder J, Pfeiffer L, Falkai P, Kirschneck M, Simon MS, Ditzen-Janotta C, Brunoni AR, Coenen M, Dong MS, Gensichen J, Glocker C, Koutsouleris N, Musil R, Schmitt A, Jung-Sievers C. Measuring social environment factors of inpatients and outpatients with depression in Germany: a cross-sectional study.
   BMJ Ment Health. 2025 April 3;28(1):e301359. Doi: 10.1136/bmjment-2024-301359
   Impact factor (2024): 3,7

5. Eder J, Dong MS, Wöhler M, Simon MS, Glocker C, Pfeiffer L, Gaus R, Wolf J, Mestan K, Krcmar H, Koutsouleris N, Schneider A, Gensichen J, Musil R, Falkai P; POKAL Group. A multimodal approach to depression diagnosis: insights from machine learning algorithm development in primary care.
   Eur Arch Psychiatry Clin Neurosci. 2025 Mar 10. Doi: 10.1007/s00406-025-01990-5
   Impact factor (2024): 3,7

6. Glocker C, Simon MS, Adler N, Eder J, Barton BB, Musil R. Development and Evaluation of the “Eating More Consciously” Module of a Lifestyle Intervention Program to prevent Medication-Induced Weight Gain in Psychiatric Patients: A One-Arm Pilot Study.
   Alpha Psychiatry. 2024 Nov 1;25(6):737-745.
   Doi: 10.5152/alphapsychiatry.2024.241718.
   Impact factor (2024): 3,5

7. Fuchs C, Silveira S, Meindl T, Musil R, Austerschmidt KL, Eilert DW, Müller N, Möller HJ, Engel R, Reiser M, Driessen M, Beblo T, Hennig-Fast K. Two Sides of Theory of Mind: Mental State Attribution to Moving Shapes in Paranoid Schizophrenia Is Independent of the Severity of Positive Symptoms.
   Brain Sci. 2024 May 2;14(5):461. Doi: 10.3390/brainsci14050461
   Impact factor (2023): 2,7

8. Eder J, Glocker C, Barton B, Sarisik E, Popovic D, Lämmermann J, Knaf A, Beqiri-Zagler A, Engl K, Rihs L, Pfeiffer L, Schmitt A, Falkai P, Simon MS, Musil R. Who is at risk for weight gain after weight-gain associated treatment with antipsychotics, antidepressants, and mood stabilizers: A machine learning approach.
   Acta Psychiatr Scand. 2024 Apr 1. Doi: 10.1111/acpd.13684.
   Impact factor (2022): 6,7

9. Mazinan RG, Dudek C, Warkentin H, Finkenstaedt M, Schröder J, Musil R, Kratzer L, Fuss J, Biedermann SV. Borderline personality disorder and sexuality: causes and consequences of dissociative symptoms.
   Borderline Personal Disord Emot Dysregul. 2024 Mar 19;11(1):8. Doi: 10.1186/s40479-024-00251-6
   Impact factor (2022): 4,1

10. Müller-Vahl KR, Pisarenko A, Ringlstetter R, Cimpianu CL, Fremer C, Weidinger E, Jenz EB, Musil R, Brunnauer A, Großhennig A. The Effect of Nabiximols on Driving Ability in Adults with Chronic Tic Disorders: Results of a Substudy Analysis of the Double-Blind, Randomized, Placebo-Controlled CANNA-TICS Trial.
    Cannabis Cannabinoid Res. 2024 Jan 23. Doi: 10.1089/can.2023.0014
    Impact factor (2023): 3,7

11. Eder J, Pfeiffer L, Wichert SP, Keeser B, Simon MS, Popovic D, Glocker C, Brunoni AR, Schneider A, Gensichen J, Schmitt A, Musil R, Falkai P. POKAL Group. Deconstructing depression by machine learning: the POKAL-PSY study.
    Eur Arch Psychiatry Clin Neurosci. 2023 Dec 13. Doi: 10.1007/s00406-023-01720-9
    Impact factor (2023): 4,7

12. Franz M, Papiol S, Simon MS, Barton BB, Glockner C, Spellmann I, Riedel M, Heilbronner U, Zill P, Schulze TG, Musil R. Association of clinical parameters and polygenic risk scores for body mass index, schizophrenia, and diabetes with antipsychotic-induced weight gain.
    J Psychiatr Res. 2023 Nov 25;169-184. Doi: 10.1016/j.jpsychires.2023.11.038.
    Impact factor (2023): 4,8

13. Kunz JI, Frey A, Bertsch K, Barton BB, Blei L, Schirle HM, Konvalin F, Jobst A, Musil R, Padberg F, Reinhard MA. Loneliness Is Associated With Lower Self- and Clinician-Rated Levels of Personality Functioning.
    J Pers Disord. 2023 Nov;37(6):724-740. Doi: 10.1521/pedi.2023.37.6.724
    Impact factor (2023): 2,3

14. Levine SM, Merz K, Keeser D, Kunz JI, Barton BB, Reinhard MAR, Jobst A, Padberg F, Neukel C, Herpertz SC, Bertsch K, Musil R. Altered amygdalar emotion space in borderline personality disorder normalizes following dialectical behaviour therapy.
    J Psychiatry Neurosci. 2023 Nov 7;48(6):E431-E438. Doi: 10.1503/jpn.230085.
    Impact factor (2023): 4,3

15. Wolf J, Reinhard MA, Goerigk S, Barton BB, Burkhardt G, Tang J, Eder J, Amann BL, Bertsch K, Jobst A, Musil R, Padberg F. Suicidal behaviors and adverse childhood experiences: A cross-diagnostic study in persistent depressive disorder and borderline personality disorder.
    Psychiatry Res. 2023 Dec;330:115562. Doi: 10.1016/j.psychres.2023.115562
    Impact factor (2023): 11,3

16. Goerigk S, Reinhard MA, Barton BB, Burkhardt G, Ehring T, Bertsch K, Amann BL, Sarubin N, Seidl E, Falkai P, Musil R, Jobst A, Padberg F. Transdiagnostic analysis of adverse childhood experiences and their association with psychopathology-A TRANS-D conform study.
    Psychiatry Res. 2023 Nov;329:115545. Doi: 10.1016/j.psychres.2023.115545
    Impact factor (2023): 11,3

17. Barton BB, Ehring T, Reinhard MA, Goerigk S, Wüstenberg T, Musil R, Amann BL, Jobst A, Dewald-Kaufmann J, Padberg F. Effects of resilience and timing of adverse and adaptive experiences on interpersonal behavior: a transdiagnostic study in a clinical sample.
    Sci Rep. 2023 Oct 24;13(1):18131. Doi: 10.1038/s41598-023-44555-z
    Impact factor (2023): 4,6

18. Seemüller F, Schennach R, Musil R, Obermeier M, Adli M, Bauer M, Brieger P, Laux G, Gaebel W, Falkai P, Riedel M, Möller HJ. A factor analytic comparison of three commonly used depression scales (HAMD, MADRS, BDI) in a large sample of depressed inpatients.
    BMC Psychiatry. 2023 Jul 28;23(1):548. Doi: 10.1186/s12888-023-05038-7
    Impact factor (2023): 4,4

19. Simon MS, Ioannou M, Arteaga-Henríquez G, Wijkhuijs A, Berghmans R, Musil R, Müller N, Drexhage HA. Premature T cell aging in major depression: A double hit by the state of disease and cytomegalovirus infection.
    Brain Behav Immun Health. 2023 Feb 27;29:100608. Doi: 10.1016/j.bbih.2023.100608
    Impact factor (2023): 5

20. Müller-Vahl KR, Pisarenko A, Szeijko N, Haas M, Fremer C, Jakubovski E, Musil R, Münchau A, Neuner I, Huys D, van Elst LT, Schröder C, Ringlstetter R, Koch A, Jenz EB, Großhennig A. CANNA-TICS: Efficacy and safety of oral treatment with nabiximols in adults with chronic tic disorders – Results of a prospective, multicenter, randomized, double-blind, placebo controlled, phase IIIb superiority study.
    Psychiatry Res. 2023 May; 323:115135. Doi: 10.1016/j.psychres.2023.115135.
    Impact factor (2023): 11,225

21. Barton BB, Reinhard MA, Goerigk S, Wüstenberg T, Musil R, Ehring T, Jobst A, Dewald-Kaufmann J, Padberg F. Association between the behavioral response during social exclusion and recalled childhood maltreatment.
    Behav Res Ther. 2023 Jan;160:104232. Doi: 10.1016/j.brat.2022.104232
    Impact factor (2021): 5,321

22. Reinhard MA, Rek SV, Nenov-Matt T, Barton BB, Dewald-Kaufmann J, Merz K, Musil R, Jobst A, Brakemeier EL, Bertsch K, Padberg F. Association of loneliness and social network size in adulthood with childhood maltreatment: Analyses of a population-based and a clinical simple.
    Eur Psychiatry. 2022 Sep 5;65(1):e55. Doi: 10.1192/j.eurpsy.2022.2313
    Impact factor (2022): 7,156

23. Wolf J, Padberg F, Nenov-Matt T, Amann BL, Barton BB, Tang J, Glessner G, Brakemeier EL, Jobst A, Musil R, Reinhard MA. Suicidal behaviors are associated with loneliness and decrease during inpatient CBASP treatment for persistent depressive disorder.
    J Psychiatr Res. 2022 Oct;154:139-144. Doi: 10.1016/j.psychires.2022.07.059
    Impact factor (2022): 5,25

24. Reinhard MA, Popov N, Rek SV, Nenov-Matt T, Barton BB, Jobst A, Musil R, Padberg F. Loneliness is associated with maladaptive schema modes in patients with persistent depressive disorder.
    J Psychiatr Res. 2022 Oct;154:56-60. Doi: 10.1016/j.jpsychires.2022.07.057
    Impact factor (2022): 5,25

25. Heres S, Cordes J, Feyerabend S, Schmidt-Kraepelin C, Musil R, Riedel M, Spellmann I, Langguth B, Landgrebe M, Fran E, Petcu CC, Hahn E, Ta TMT, Matei V, Dehelean L, Papaca I, Leweke FM, van der List T, Tamasan SC, Lang FU, Naber D, Ruhrmann S, Wolff-Menzler C, Juckel G, Ladea M, Stefanescu C, Lautenschlager M, Bauer M, Zamora D, Horowitz M, Davis JM, Leucht S. Changing the Antipsychotic in Early Nonimprovers to Amisulpride or Olanzapine: Randomized, Double-Blind Trial in Patients With Schizophrenia.
    Schizoph Bull. 2022 Nov 18;48(6):1273-1283. Doi: 10.1093/schbul/sbac068.
    Impact factor (2022): 9,306

26. Simon MS, Barton BB, Zagler A, Engl K, Rihs L, Glocker C, Musil R. Lifestyle behaviors, metabolic disturbances, and weight gain in psychiatric inpatients treated with weight gain-associated medication.
    Eur Arch Psychiatry Clin Neurosci. 2022 Jul1 doi: 10.1007/s00406-022-01442-4
    Impact factor (2020): 5,276

27. Sabaß L, Buchenrieder N, Rek SV, Nenov-Matt T, Lange J, Barton BB, Musil R, Jobst A, Padberg F, Reinhard MA. Attachment mediates the link between childhood maltreatment and loneliness in persistent depressive disorder.
    J Affect. Disord. 2022 Jun 18:S0165-0327(22)00681-4. doi: 10.1016/j.jad.2022.06.021.
    Impact factor (2021-2022): 4,839

28. Haas M, Jakubovski E, Kunert K, Fremer C, Buddensiek N, Häckl S, Lenz-Ziegenbein M, Musil R, Roessner V, Münchau A, Neuner I, Koch A, Müller-Vahl K. ONLINE-TICS: Internet-Delivered Behavioral Treatment for Patients with Chronic Tic Disorders
    J Clin Med. 2022 Jan 4;11(1):250. doi: 10.3390/jcm11010250.
    Impact factor (2020): 4,242

29. Seemüller F, Kolter M, Musil R, Schennach R, Adli M, Bauer M, Brieger P, Laux G, Riedel M, Falkai P, Müller HJ, Padberg F. Chronic vs non-chronic depression in psychiatric inpatient care – Data from a large naturalistic multicenter trial.
    J Affect Disord. 2021 Nov 17;299:73-84. doi: 10.1016/j.jad.2021.11.042.
    Impact factor (2020-2021): 4,839

30. Barton BB, Goerigk S, Wüstenberg T, Dewald-Kaufmann J, Reinhard MA, Musil R, Ehring T, Jobst A, Padberg F. Altered immediate behavioral response to partial social exclusion: A cross-diagnostic study in patients with borderline personality disorder and persistent depressive disorder.
    J Psychiatr Res. 2021 Oct 14; 144: 177-183. doi:10.1016/j.jpsychires.2021.10.005.
    Impact factor (2020): 3,301

31. Simon MS, Burger B, Weidinger E, Arteaga-Henríquez G, Zill P, Musil R, Drexhage HA, Müller N. Efficacy of Sertraline Plus Placebo or Add-On Celecoxib in Major Depressive Disorder: Macrophage Migration Inhibitory Factor as a Promising Biomarker for Remission After Sertraline - Results From a Randomized Controlled Clinical Trial. Front Psychiatry. 2021 Sep 27;12:615261.
    doi: 10.3389/fpsyt.2021.615261.eCollection 2021.
    Impact factor (2020): 4,157

32. Reinhard MA, Padberg F, Dewald-Kaufmann J, Wüstenberg T, Goerigk S, Barton BB, Zülch A, Brandl L, Windmüller H, Fernandes F, Brunoni AR, Musil R, Jobst A. Sequential Social Exclusion in a Novel Cyberball Paradigm Leads to Reduced Behavioral Repair and Plasma Oxytocin in Borderline Personality Disorder. J Pers Disord. 2021 Aug 24;1-17.
    doi: 10.1521/pedi_2021_35_532.
    Impact factor (2020-2021): 3,132

33. Simon MS, Schiweck C, Arteaga-Henríquez G, Poletti S, Haarman BCM, Dik WA, Schwarz M, Vrieze E, Mikova O, Joergens S, Musil R, Claes S, Baune BT, Leboyer M, Benedetti F, Furlan R, Berghmans R, de Wit H, Wijkhuijs A, Arolt V, Müller N, Drexhage HA. Monocyte mitochondrial dysfunction, inflammaging, and inflammatory pyroptosis in major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2021 Dec 20;111:110391.
    doi: 10.1016/j.pnpbp.2021.110391. Epub 2021 Jun 23.
    Impact factor (2020): 5,067

34. Konvalin F, Grosse-Wentrup F, Nenov-Matt T, Fischer K, Barton BB, Goerigk S, Brakemeier E-L, Musil R, Jobst A, Padberg F, Reinhard MA. Borderline Personality Features in Patients With Persistent Depressive Disorder and Their Effect on CBASP Outcome. Front Psychiatry. 2021 Mar 12;12:608271.
    doi: 10.3389/fpsyt.2021.608271. eCollection 2021.
    Impact factor (2020): 4,157

35. Kai F Fischer, Simon MS, Elsner J, Dobmeier J, Dorr J, Blei L, Zill P, Obermeier M, Musil R. Assessing the links between childhood trauma, C-reactive protein and response to antidepressant treatment in patients with affective disorders. Eur Arch Psychiatry Clin Neurosci. 2021 Oct;271(7):1331-1341.
    doi: 10.1007/s00406-021-01245-z. Epub 2021 Mar 17.
    Impact factor (2020): 5,270

36. Dewald-Kaufmann JF, Wüstenberg T, Barton BB, Goerigk S, Reinhard MA, Musil R, Werle J, Falkai P, Jobst A, Padberg F. Dynamics of the immediate behavioral response to partial social exclusion.
    Sci Rep. 2021 Jan 20;11(1):1853. Doi: 10.1038/s41598-020-80039-0
    Impact factor (2019): 4,379

37. Nenov-Matt T, Barton BB, Dewald-Kaufmann J, Goerigk S, Rek S, Zentz K, Musil R, Jobst A, Padberg F, Reinhard MA. Loneliness, Social Isolation and Their Difference: A Cross-Diagnostic Study in Persistent Depressive Disorder and Borderline Personality Disorder
    Front Psychiatry. 2020 Dec 17;11:608476. Doi: 10.3389/fpsyt.2020.608476
    Impact factor (2020): 4,157

38. Schennach R, Riedel M, Obermeier M, Jäger M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke MR, Rüther E, Klingberg S, Gastpar M, Seemüller F, Spellmann I, Musil R, Möller HJ. What Happens With Schizophrenia Patients After Their Discharge From Hospital? Results on Outcome and Treatment From a “Real-World” 2-year Follow-Up Trial
    Eur Arch Psychiatry Clin Neurosci 2019 Aug 28[Online ahead of print]. doi: 10.1007/s00406-019-01055-4
    Impact factor (2019): 3,192

39. Barton B, Zagler A, Engl K, Rihs L, Musil R. Prevalence of obesity, metabolic syndrome, diabetes and risk of cardiovascular disease in a psychiatric inpatient sample: Results of the Metabolism in Psychiatry (MiP) Study
    Eur Arch Psychiatry Clin Neurosci 2019 Jul 13[Online ahead of print]. doi: 10.1007/s00406-019-01043-8
    Impact factor (2019): 3,192

40. Arteaga-Henriquez G, Simon MS, Burger B, Weidinger E, Wijkhuijs A, Arolt V, Birkenhager TK, Musil R, Müller N, Drexhage HA. Low grade inflammation as a predictor of antidepressant and anti-inflammatory therapy response in MDD patients. A systematic review of the literature in combination with an analysis of experimental data collected in the EU-MOODINFLAME consortium
    Frontiers Psychiatry 2019 Jul 9, 10, 458. doi: 10.3389/fpsyt.2019.00458,
    Impact factor (2018): 3,532

41. Schennach R, Obermeier M, Spellmann I, Seemüller F, Musil R, Jäger M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Bauer M, Adli M, Zeiler J, Bender W, Kronmüller KT, Ising M, Brieger P, Maier W, Lemke MR, Rüther E, Klingberg S, Gastpar M, Möller HJ, Riedel M. Remission in schizophrenia – What are we measuring? Comparing the consensus remission criteria to a CGI-based definition of remission and to remission in major depression
    Schizophr Res. 2019 May 25, pii: S0920-9964(19)30155-0. doi: 10.1016/j.schres.2019.04.022.
    Impact factor (2018): 3,958

42. Kirchner SK, Ozkan S, Musil R, Spellmann I, Kannayian N, Falkai P, Rossner M, Papiol S. Polygenic analysis suggests the involvement of calcium signaling in executive function in schizophrenia Patients
    Eur Arch Psychiatry Clin Neurosci. 2018 Dec 7. Doi: 10.1007/s00406-018-0961-8.
    Impact factor (2017): 3,617

43. Schennach R, Riedel M, Spellmann I, Musil R, Obermeier M, Jäger M, Bottlender R, Schaumss M, Laux G, Möller HJ. Comparing schizophrenia patients with a predicted high/low risk of nonresponse receiving treatment with ziprasidone and haloperidol: a randomized-controlled study
    Pharmacopsychiatry. 2018 Sep 20. doi: 10.1055/a-0669-9461. [Epub ahead of print]
    Impact factor (2017): 2,064

44. Musil R, Seemüller F, Meyer S, Spellmann I, Adli M, Bauer M, Kronmüller K-T, Brieger P, Laux G, Bender W, Heuser I, Fisher R, Gaebel W, Schennach R, Möller H-J, Riedel M. Subtypes of depression and their overlap in a naturalistic inpatient sample of major depressive disorder
    Int J Methods Psychiatr Res. 2018 Mar;27(1). doi: 10.1002/mpr.1569. Epub 2017 Jun 14.
    Impact factor (2017): 2,500

45. Spellmann I, Reinhard MA, Veverka D, Zill P, Obermeier M, Dehning S, Schennach R, Müller N, Riedel M, Musil R. QTc prolongation in short-term treatment of schizophrenia patients: effects of different antipsychotics and genetic factors.
    Eur Arch Psychiatry Clin Neurosci. 2018 Jun;268(4):383-390. doi: 10.1007/s00406-018-0880-8. Epub 2018 Feb 10.
    Impact factor (2017): 3,617

46. Schennach R, Obermeier M, Seemüller F, Jäger M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter, J, Heuser I, Maier W, Lemke MR, Rüther E, Klingberg S, Gastpar M, Spellmann I, Musil R, Möller HJ, Riedel M. Add-on Antidepressants in the Naturalistic Treatment of Schizophrenia Spectrum Disorder – When, Who, and How?
    Pharmacopsychiatry. 2017 Jul;50(4):136-144. doi: 10.1055/s-0043-106436. Epub 2017 May 15.
    Impact factor (2017): 2,064

47. Spellmann I, Riedel M, Städtler J, Zill P, Obermeier M, Cerovecki A, Dehning S, Schennach R, Epple M, Opgen-Rhein M, Müller N, Bondy B, Möller H-J, Musil R. Associations of NEUROD2 polymorphisms and change of cognitive dysfunctions in schizophrenia and schizoaffective disorder after eight weeks of antipsychotic treatment.
    Cogn Neuropsychiatry. 2017 Jul;22(4):280-297. doi: 10.1080/13546805.2017.1322502. Epub 2017 May 4.
    Impact factor (2017): 1,329

48. Krause D, Myint AM, Schuett C, Musil R, Dehning S, Cerovecki A, Riedel M, Arolt V, Schwarz MJ, Müller N. High Kynurenine (a Tryptophan Metabolite) Predicts Remission in Patients with Major Depression to Add-on Treatment with Celecoxib.
    Front Psychiatry. 2017 Feb 13;8:16 doi: 10.3389/fpsyt.2017.00016. eCollection 2017.
    Impact factor (2017): 2,857

49. Spellmann I, Schennach R, Seemüller F, Meyer S, Musil R, Jäger M, Schmauß M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Bauer M, Adli M, Zeiler J, Bender W, Kronmüller KT, Ising M, Brieger P, Maier W, Lemke MR, Rüther E, Klingberg S, Gastpar M, Riedel M, Möller HJ. Validity of remission and recovery criteria for schizophrenia and major depression: comparison of the results of two one-year follow-up naturalistic studies.
    Eur Arch Psychiatry Clin Neurosci. 2017 Jun;267(4):303-313. doi: 10.1007/s00406-016-0741-2. Epub 2016 Oct 26.
    Impact factor (2017): 3,617

50. Schennach R, Möller HJ, Obermeier M, Seemüller F, Jäger M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke MR, Rüther E, Klingberg S, Gastpar M, Musil R, Spellmann I, Riedel M. Challenging the understanding of significant improvement and outcome in schizophrenia - the concept of reliable and clinically significant change methods.
    Int J Methods Psychiatr Res. 2016 Mar;25(1):3-11. doi: 10.1002/mpr.1476. Epub 2015 Jul 14.
    Impact factor (2016): 3,176

51. Schennach R, Riedel M, Obermeier M, Spellmann I, Musil R, Jäger M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke MR, Rüther E, Klingberg S, Gastpar M, Möller HJ. What are residual symptoms in schizophrenia spectrum disorder? Clinical description and 1-year persistence within a naturalistic trial.
    Eur Arch Psychiatry Clin Neurosci. 2015 Mar;265(2):107-16. doi: 10.1007/s00406-014-0528-2. Epub 2014 Sep 27.
    Impact factor (2015): 4,113

52. Seemüller F, Meier S, Obermeier M, Musil R, Bauer M, Adli M, Kronmüller K, Holsboer F, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Riedel M, Falkai P, Möller H-J. Three-Year long-term outcome of 458 naturalistically treated inpatients with major depressive episode: severe relapse rates and risk factors.
    Eur. Arch. Psychiatry Clin. Neurosci. (2014) 264, 567–575. doi: 10.1007/s00406-014-0495-7. Epub 2014 Mar 4.
    Impact factor (2014): 3,35

53. Spellmann I, Rujescu D, Musil R, Meyer S, Giegling I, Genius J, Zill P, Dehning S, Cerovecki , Seemüller F, Schennach R, Hartmann AM, Schäfer M, Müller N, Möller H-J, Riedel M. Pleckstrin homology domain containing 6 protein (PLEKHA6) polymorphisms are associated with psychopathology and response to treatment in schizophrenic patients.
    Prog. Neuropsychopharmacol. Biol. Psychiatry 2014 Jun 3;51:190-5. doi: 10.1016/j.pnpbp.2014.02.006. Epub 2014 Feb 25
    Impact factor (2014): 3,7

54. Musil R, Zill P, Seemüller F, Bondy B, Obermeier M, Spellmann I, Bender W, Adli M, Heuser I, Zeiler J, Gaebel W, Maier W, Rietschel M, Rujescu D, Schennach R, Möller H-J, Riedel M. No influence of brain-derived neurotrophic factor (BDNF) polymorphisms on treatment response in a naturalistic sample of patients with major depression.
    Eur Arch Psychiatry Clin Neurosci. 2013 Aug;263(5):405-12. doi: 10.1007/s00406-012-0364-1. Epub 2012 Sep 11.
    Impact factor (2014): 3,55

55. Musil R, Zill P, Seemüller F, Bondy B, Meyer S, Spellmann I, Bender W, Adli M, Heuser I, Fisher R, Gaebel W, Maier W, Rietschel M, Rujescu D, Schennach R, Möller H-J, Riedel M. Genetics of emergent suicidality during antidepressive treatment--data from a naturalistic study on a large sample of inpatients with a major depressive episode.
    Eur Neuropsychopharmacol. 2013 Jul;23(7):663-74. doi: 10.1016/j.euroneuro.2012.08.009. Epub 2012 Oct 11.
    Impact factor (2013): 5,39

56. Seemüller F, Lewitzka U, Bauer M, Meyer S, Musil R, Schennach R, Riedel M, Doucette S, Möller HJ. The Relationship of Akathisia with Treatment Emergent Suicidality among Patients with First-Episode Schizophrenia Treated with Haloperidol or Risperidone.
    Pharmacopsychiatry. 2012 Nov;45(7):292-6. doi: 10.1055/s-0032-1309004. Epub 2012 May 21
    Impact Factor (2012): 2,071

57. Seemüller F, Schennach R, Mayr A, Musil R, Jäger M, Maier W, Klingenberg S, Heuser I, Klosterkötter J, Gastpar M, Schmitt A, Schlösser R, Schneider F, Ohmann C, Lewitzka U, Gaebel W, Möller H-J, Riedel M, German Study Group on First-Episode Schizophrenia. Akathisia and suicidal ideation in first-episode schizophrenia.
    J. Clin. Psychopharmacol. (2012) 32, 694–698. doi:10.1097/JCP.0b013e3182677958
    Impact factor (2012): 3,51

58. Schennach, R., Meyer, S., Seemüller, F., Jäger, M., Schmauss, M., Laux, G., Pfeiffer, H., Naber, D., Schmidt, L.G., Gaebel, W., Klosterkötter, J., Heuser, I., Maier, W., Lemke, M.R., Rüther, E., Klingberg, S., Gastpar, M., Musil, R., Möller, H.-J., Riedel, M. Response trajectories in “real-world” naturalistically treated schizophrenia patients.
    Schizophr Res. 2012 Aug;139(1-3):218-24. doi: 10.1016/j.schres.2012.05.004. Epub 2012 Jun 2.
    Impact factor (2012): 4,59

59. Schennach R, Riedel M, Musil R, Möller HJ. Treatment Response in First-episode Schizophrenia. Clin Psychopharmacol Neurosci. 2012 Aug;10(2):78-87. doi: 10.9758/cpn.2012.10.2.78. Epub 2012 Aug 31.
    Impact factor (2012): 4,59

60. Spellmann I, Riedel M, Schennach R, Seemüller F, Obermeier M, Musil R, Schmauß M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke MR, Rüther E, Klingberg S, Gastpar M, Möller HJ. One-year functional outcomes of naturalistically treated patients with schizophrenia.
    Psychiatry Res. 2012 Aug 15;198(3):378-85. doi: 10.1016/j.psychres.2011.12.047. Epub 2012 Mar 14.
    Impact Factor (2012): 2,524

61. Schennach R, Zill P, Obermeier M, Hauer D, Dehning S, Cerovecki A, Opgen-Rhein M, Musil R, Spellmann I , Matz J, Krause D, Seemüller F, Müller N, Möller H-J, Bondy B, Riedel M. The CNR1 gene in depression and schizophrenia - is there an association with early improvement and response?
    Psychiatry Res. 2012 Mar 30;196(1):160. doi: 10.1016/j.psychres.2011.11.021. Epub 2012 Feb 25.
    Impact factor (2012): 4,06

62. Musil R, Schwarz MJ, Riedel M, Dehning S, Cerovecki A, Spellmann I, Arolt V, Müller N. Elevated macrophage migration inhibitory factor and decreased transforming growth factor-beta levels in major depression--no influence of celecoxib treatment.
    J Affect Disord. 2011 Nov;134(1-3):217-25. doi: 10.1016/j.jad.2011.05.047. Epub 2011 Jun 17.
    Impact Factor (2010): 3,740

63. Riedel M, Spellmann I, Schennach-Wolff R, Obermeier M, Musil R. The RSM-scale: a pilot study on a new specific scale for self- and observer-rated quality of life in patients with schizophrenia.
    Qual Life Res. 2011 Mar;20(2):263-72. doi: 10.1007/s11136-010-9744-z. Epub 2010 Oct 5.
    Impact Factor (2010): 2,376

64. Riedel M, Severus E, Schennach-Wolff R, Musil R, Spellmann I, Oppolzer B, Möller HJ, Köhler J, Seemüller F, (2011). Effectiveness of quetiapine in outpatients with schizophrenia assessed under "real-life" conditions: a German clinical-practice evaluation programme.
    J Clin Psychopharmacol. 2011 Feb;31(1):120-2. doi: 10.1097/JCP.0b013e3182061184.
    Impact factor (2010): 4,86

65. Spellmann I, Rujescu D, Musil R, Mayr A, Giegling I, Genius J, Zill P, Dehning S, Opgen-Rhein M, Cerovecki A, Hartmann AM, Schäfer M, Bondy B, Müller N, Möller HJ, Riedel M. Homer-1 polymorphisms are associated with psychopathology and response to treatment in schizophrenic patients.
    J Psychiatr Res. 2011 Feb;45(2):234-41. doi: 10.1016/j.jpsychires.2010.06.004. Epub 2010 Jul 3.
    Impact Factor (2010): 3,723

66. Müller N, Krause D, Dehning S, Musil R, Schennach-Wolff R, Obermeier M, Möller HJ, Klauss V, Schwarz MJ, Riedel M. Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment.
    Schizophr Res. 2010 Aug;121(1-3):118-24. doi: 10.1016/j.schres.2010.04.015. Epub 2010 May 31.
    Impact Factor (2010): 4,458

67. Seemüller F, Riedel M, Obermeier M, Bauer M, Adli M, Kronmüller K, Holsboer F, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Dichgans E, Bottländer R, Musil R, Möller HJ, (2010). Outcomes of 1014 naturalistically treated inpatients with major depressive episode.
    Eur Neuropsychopharmacol. 2010 May;20(5):346-55. doi: 10.1016/j.euroneuro.2009.11.011. Epub 2010 Jan 22.
    Impact factor (2010): 4,20

68. Riedel M, Schennach-Wolff R, Musil R, Dehning S, Cerovecki A, Opgen-Rhein M, Matz J, Seemüller F, Obermeier M, Engel RR, Müller N, Möller HJ, Spellmann I, (2010). Neurocognition and its influencing factors in the treatment of schizophrenia-effects of aripiprazole, olanzapine, quetiapine and risperidone.
    Hum Psychopharmacol. 2010 Mar;25(2):116-25. doi: 10.1002/hup.1101.
    Impact factor (2010): 2,60

69. Riedel M, Spellmann I, Schennach-Wolff R, Musil R, Dehning S, Cerovecki A, Opgen-Rhein M, Matz J, Seemüller F, Obermeier M, Severus E, Engel RR, Müller N, Möller HJ, (2010). Effect of aripiprazole on cognition in the treatment of patients with schizophrenia.
    Pharmacopsychiatry. 2010 Mar;43(2):50-7. doi: 10.1055/s-0029-1239539. Epub 2009 Dec 10.
    Impact factor (2010): 2,20

70. Dehning S, Müller N, Matz J, Bender A, Kerle I, Benninghoff J, Musil R, Spellmann I, Bondy B, Möller HJ, Riedel M, Zill P. A genetic variant of HTR2C may play a role in the manifestation of Tourette syndrome.
    Psychiatr Genet. 2010 Feb;20(1):35-8. doi: 10.1097/YPG.0b013e32833511ce.
    Impact Factor (2010): 2,696

71. Musil R, Spellmann I, Riedel M, Dehning S, Douhet A, Maino K, Zill P, Müller N, Möller HJ, Bondy B. SNAP-25 gene polymorphisms and weight gain in schizophrenic patients.
    J Psychiatr Res. 2008 Oct;42(12):963-70. doi: 10.1016/j.jpsychires.2007.11.003. Epub 2008 Jan 8.
    Impact Factor (2008): 4,679

72. Spellmann I, Muller N, Musil R, Zill P, Douhet A, Dehning S, Cerovecki A, Bondy B, Möller HJ, Riedel M. Associations of SNAP-25 polymorphisms with cognitive dysfunctions in Caucasian patients with schizophrenia during a brief trail of treatment with atypical antipsychotics.
    Eur Arch Psychiatry Clin Neurosci. 2008 Sep;258(6):335-44. doi: 10.1007/s00406-007-0800-9. Epub 2008 Mar 17.
    Impact Factor (2008): 2,852

73. Riedel M, Muller N, Spellmann I, Engel RR, Musil R, Valdevit R, Dehning S, Douhet A, Cerovecki A, Strassnig M, Moller HJ. Efficacy of olanzapine versus quetiapine on cognitive dysfunctions inpatients with an acute episode of schizophrenia.
    Eur Arch Psychiatry Clin Neurosci. 2007 Oct;257(7):402-12.
    Impact Factor (2007): 2,809

74. Riedel M, Muller N, Strassnig M, Spellmann I, Engel RR, Musil R, Dehning S, Douhet A, Schwarz MJ, Moller HJ. Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms.
    Eur Arch Psychiatry Clin Neurosci. 2005 Dec;255(6):432-7. Epub 2005 Nov 4.
    Impact Factor (2005): 2,264

Kumulativer impact factor Originalarbeiten: 311,244

In gelisteten peer-reviewed Journals

1. Kuang HJ, Yang HS, Feng YX, Tang H, Fan Q, Xu YQ, Cui S, Musil R, Luxenburger H, Zhang YX, Zhao H, Zhang YQ. Efficacy and safety of acupuncture therapies for adult patients with mild and moderate major depressive disorder: A systematic review and meta-analysis.
   J Integr Med. 2025 Jun 30:S2095-4964(25)00099-8. Doi: 10.1016/j.joim.2025.06.008.
   Impact factor (2024): 4,0

2. Hofer EM, Musil R, Strupp L, Falkai P, Strupp M, Schindlbeck KA. Tourette syndrome: effects of acetyl-leucine in two individuals.
   J Neurol. 2025 May;272(6):408. Doi: 10.1007/s00415-025-13136-7
   Impact factor (2024): 4,6

3. Kathan A, Amiriparian S, Triantafyllopoulos A, Gebhard A, Milkus S, Hohmann J, Muderlak P, Schottdorf J, Musil R, Schuller BW. Personalised Speech-Based PTSD Prediction Using Weighted-Instance Learning.
   Annu Int Conf IEEEE Eng Med Biol Soc. 2024 Jul;2024:1-4. Doi: 10.1109/EMBC53108.2024.10782220
   Impact factor (2024): 0,99

4. Eder J, Simon MS, Glocker C, Musil R. [Weight gain and treatment with psychotropic drugs: Background and management].
   Nervenarzt. 2023 Sep;94(9):859-869. Doi: 10.1007/s00115-023-01534-z
   Impact factor (2023): 1,0

5. Paschou P, Jin Y, Müller-Vahl K, Möller HE, Rizzo R, Hoekstra PJ, Roessner V, Mol Debes N, Worbe Y, Hartmann A, Mir P, Cath D, Neuner I, Eichele H, Zhang C, Lewandowska K, Munchau A, Verrel J, Musil R, Silk TJ, Hanlon CA, Bihun ED, Brandt V, Dietrich A, Forde N, Ganos C, Greene DJ, Chu C, Grothe MJ, Hershey T, Janik P, Koller JM, Martin-Rodriguez JG, Müller K, Palmucci S, Prato A, Ramkiran S, Saia F, Szejko N, Torrecuso R, Tumer Z, Uhlmann A, Veselinovic T, Wolanczyk T, Zouki JJ, Jain P, Topaloudi A, Kaka M, Yang Z, Drineas P, Thomopoulos SI, White T, Veltman DJ, Schmaal L, Stein DJ, Buitelaar J, Franke V, van den Heuvel O, Jahanshad N, Thompson PM, Black KJ. Enhancing neuroimaging genetics through meta-analysis for Tourette syndrome (ENIGMA-TS): A worldwide platform for collaboration.
   Front Psychiatry. 2022 Aug 18;13:958688. Doi:3389/fpsyt.2022.958688
   Impact factor (2021): 5,435

6. Kalman JL, Burkhardt G, Adorjan K, Barton BB, De Jonge S, Eser-Valeri D, Falter-Wagner CM, Heilbronner U, Jobst A, Keeser D, Koenig C, Koller G, Koutsouleris N, Kurz C, Landgraf D, Merz K, Musil R, Nelson AM, Padberg F, Papiol S, Pogarell O, Perneczky R, Raabe F, Reinhard MA, Richter A, Rüther T, Simon MS, Schmitt A, Slapakova L, Scheel N, Schüle C, Wagner E, Wichert SP, Zill P, Falkai P, Schulze TG, Schulte EC. Biobanking in everyday clinical practice in psychiatry – The Munich Mental Health Biobank.
   Front Psychatr. 2022 Jul 22;13:934640. Doi: 10.3389/fpsyt.2022.934640
   Impact factor (2021): 5,435

7. Bousman CA, Bengesser SA, Aitchison KJ, Amare AT, Aschauer H, Baune BT, Asl BB, Bishop JR, Burmeister M, Chaumette B, Chen LS, Cordner ZA, Deckert J, Degenhardt F, DeLisi LE, Folkersen L, Kennedy JL, Klein TE, Mc Clay JL, McMahon FJ, Musil R, Saccone NL, Sangkuhl K, Stowe RM, Tan EC, Tiwari SAK, Zai CC, Zai G, Zhang J, Gaedigk A, Müller DJ. Review and Consensus on Pharmacogenomic Testing in Psychiatry
   Pharmacopsychiatry. 2021 Jan;54(1):5-17. doi: 10.1055/a-1288-1061. Epub 2020 Nov 4
   Impact Factor (2019): 5,788

8. Barton BB, Segger F, Fischer K, Obermeier M, Musil R. Update on weight-gain caused by antipsychotics: a systematic review and meta-analysis
   Expert Opin Drug Saf. 2020 Mar;19(3):295-314. doi: 10.1080/14740338.2020.1713091. Epub 2020 Mar 12
   Impact Factor (2019): 3,320

9. Reinhard MA, Dewald-Kaufmann J, Wüstenberg T, Musil R, Barton B, Jobst A, Padberg F. The Vicious Circle of Social Exclusion and Psychopathology; A Systematic Review of Experimental Ostracism Research in Psychiatric Disorders
   Eur Arch Psychiatry Clin Neurosci 2019 Oct 4[Online ahead of print]. DOI: 10.1007/s00406-019-01074-1
   Impact Factor (2019): 3,192

10. Schnell J, Weidinger E, Musil R. Patienten mit Tic-Störungen: weit bekannt, doch unterversorgt / Patients with tic disorders: widely known, yet underserved
    Fortschr Neurol Psychiatr 2019; 87: 577–589. doi: 10.1055/a-0996-0944
    Impact Factor (2019): 0,635

11. Reedtz C, van Doesum K, Signorini G, Lauritzen C, van Amelsvoort T, van Santvoort F, Young AH, Conus P, Musil R, Schulze T, Berk M, Stringaris A, Piché G, de Girolamo G. Promotion of Wellbeing for children of Parents With Mental Illness: A Model Protocol for Research and Intervention
    Front Psychiatry, 2019 Sep 6, 10, 606. doi: 10.3389/fpsyt.2019.00606
    Impact Factor (2017): 3,532

12. Musil R, Spellmann I. Pharmacogenetics and cognitive symptoms in schizophrenia patients treated with antipsychotics
    Pharmacogenomics. 2018 Aug 1;19(12):927-930. doi: 10.2217/pgs-2018-0083. Epub 2018 Jul 20.
    Impact Factor (2017): 2,302

13. Musil R, Obermeier M, Russ P, Hamerle M. Weight gain and antipsychotics: a drug safety review.
    Expert Opin Drug Saf. 2015 Jan;14(1):73-96. doi: 10.1517/14740338.2015.974549. Epub 2014 Nov 15.
    Impact Factor (2015): 2,264

14. Cerovecki, A., Musil, R., Klimke, A., Seemüller, F., Haen, E., Schennach, R., Kühn, K.-U., Volz, H.-P., Riedel, M. (2013). Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations. CNS Drugs 27, 545–572. doi:10.1007/s40263-013-0079-5
    Impact factor (2014): 4,38

15. Berger M, Musil R, Seemüller F, (2014). [Long-term treatment of bipolar disorder]
    Fortschr Neurol Psychiatr. 2014 Jun;82(6):346-58; quiz 359-60. doi: 10.1055/s-0034-1366575. Epub 2014 Jun 5.
    Impact factor (2013): 0,629

16. Seemüller F, Berger M, Musil R, Severus E, Dittmann S, Born C, Schaub A, Dargel S, Grunze H, (2013). [The challenge of treating bipolar outpatients].
    Fortschr Neurol Psychiatr. 2013 May;81 Suppl 1:S35-9. doi: 10.1055/s- 0033-1335275. Epub 2013 May 16. German.
    Impact factor (2013): 0,762

17. Schennach R, Musil R, Möller HJ, Riedel M. Functional outcomes in schizophrenia: employment status as a metric of treatment outcome.
    Curr Psychiatry Rep. 2012 Jun;14(3):229-36. doi: 10.1007/s11920-012-0261-3.
    Impact factor (2013): 3,238

18. Seemüller F, Möller HJ, Dittmann S, Musil R. Is the efficacy of psychopharmacological drugs comparable to the efficacy of general medicine medication?
    BMC Med. 2012 Feb 15;10:17. doi: 10.1186/1741-7015-10-17.
    Impact factor (2013): 6,1

Kumulativer impact factor Übersichtsarbeiten: 57,602

1. Behler N, Leitner B, Mezger E, Weidinger E, Musil R, Blum B, Kirsch B, Wulf L, Löhrs L, Winter C, Padberg F, Palm U. Cathodal tDCS over motor cortex does not improve Tourette Syndrome: Lessons learned from a case series
   Front. Behav. Neurosci. 2018; 12:194. doi: 10.3389/fnbeh.2018.00194
   Impact factor (2017): 3,138

2. Richieri R, Blackman G, Musil R, Spatola, Cavanna AE, Lancon C, Régis J. Positive clinical effects of gamma knife capsulotomy in a patient with deep brain stimulation-refractory Tourette Syndrome and Obsessive Compulsive Disorder.
   Clin Neurol Neurosurg. 2018 Jul;170:34-37. doi: 10.1016/j.clineuro.2018.04.018. Epub 2018 Apr 26
   Impact factor (2017): 1,736

3. Nowidi K, Kunisch R, Bouna-Pyrrou P, Meißner D, Hennig-Fast K, Weindl A, Förster S, Neuhann TM, Falkai P, Berger M, Musil R. [The White man's burden - a case study caught between bipolar affective disorder and Huntington's disease].
   Fortschr Neurol Psychiatr. 2013 Jun;81(6):337-45. doi: 10.1055/s-0033-1335040. Epub 2013 Apr 23. German
   Impact factor (2013): 0,762

Kumulativer impact factor Fallberichte: 5,636

1. Schottdorf J, Musil R. Behandlung von chronischem Rückenschmerz mit expositionsgestützter Trauma-Akupunkturtherapie (EX.TRACT): Eine Fallbeschreibung
   Deutsche Zeitschrift für Akupunktur 2025 Jul.
   Impact factor (2025): 0,1

2. Musil R. Traumaakupunktur im Team – Integrative Therapie in der akutpsychosomatischen Klinik
   Deutsche Zeitschrift für Akupunktur 2025 Jul.
   Impact factor (2025): 0,1

3. Schottdorf J, Musil R. Behandlung von postpartaler Depression mit Akupunktur: Expositionsgestützte Traumaakupunkturtherapie (EX.TRACT)
   Deutsche Zeitschrift für Akupunktur 2024 Oct.
   Impact factor (2024): 0,1

4. Kathan A, Bürger M, Triantafyllopoulos, Milkus S, Hohmann J, Muderlak P, Schottdorf J, Musil R, Schuller B, Amiriparian S. Real-world PTSD Recognition: A Cross-corpus and Cross-linguistic Evaluation
   Conference: Interspeech 2024 Sep. Doi: 10.21437/Interspeech.2024-493

5. Schottdorf J, Musil R. Behandlung von psychischen Traumata mit Akupunktur: Expositionsgestützte Trauma-Akupunktur-Therapie (EX.TRACT)
   Deutsche Zeitschrift für Akupunktur 2024 Jun.
   Impact factor (2024): 0,1

6. Musil R, Hofer E-M, Colling C. Akupunktur in der Psychiatrie - Chancen und Grenzen
   Zeitschrift für Komplementärmedizin 2021; 13(06): 36-40 doi: 10.1055/a-1663-5248

7. Barton BB, Simon MS, Glocker C, Musil R. Was tun, wenn das Körpergewicht ansteigt?
   InFo Neurologie & Psychiatrie 2020 Dec 22(12) doi: 10.1007/s15005-020-1555-3

8. Musil R, Falkai P. Neuro-psychopharmacotherapy and the Differential Diagnostic Approaches in Europe
   Kapitel in “NeuroPsychopharmacotherapy” doi: 10.1007/978-3-319-56015-1_367-1

9. Barton B, Musil R. Posttraumatische Belastungsstörung
   Deutsche Zeitschrift für Akupunktur 2019 Feb. 62(1):24-27 doi: 10.1007/s42212-018-0128-6

10. Musil R. Tourette Syndrom - Aktuelle Therapieansätze
    CliniCum neuropsy 2018, 4/18; 2-4

11. Schnell JML, Weidinger E, Musil R. Patienten mit Tics [Patients with tics]
    MMW Fortschr Med. 2018 Sep;160(15):47-50. doi: 10.1007/s15006-018-0886-1. Review.

12. Musil R. Verbesserte Fähigkeit zur Emotionsregulation.
    InFo Neurologie & Psychiatrie 2017 Aug., Vol. 19, Issue 7-8, pp 24-24 Journal Club

13. Anetzberger F, Meinhardt J, Musil R. Dialektisch-behaviorale Therapie – eine Übersicht
    Ärztliche Psychotherapie 2017 3, Schattauer GmbH, Schwerpunkt

14. Schottdorf J, Musil R. Psychische Traumatherapie mit akupunkturgestützter Exposition in drei Schritten.
    Deutsche Zeitschrift für Akupunktur 2017 Jan. 60(4):6-12 DOI: 10.1016/S0415-6412(17)30113-3 Innovation

15. Kloiber S, Musil R. Akupunktur bei psychiatrischen Erkrankungen – Literaturüberblick und Entwicklungsmöglichkeiten. Teil 3: Somatoforme Störungen, Posttraumatische Störungen, bipolare Störungen, Zwangserkrankungen, Schlafstörungen, Schizophrenie.
    Deutsche Zeitschrift für Akupunktur 2016;59(1):6-9.

16. Musil R. Chinesische Medizin und Psychotherapie – ein Blick nach vorn.
    Deutsche Zeitschrift für Akupunktur 2016;59(1):10. Kommentar

17. Musil R. Rapid Onset of the Effects of Combined Selective Serotonin Reuptake Inhibitors and Electroacupuncture on Primary Depression: A Meta-Analysis
    Deutsche Zeitschrift für Akupunktur 2016 Dec. 59(3):27-29. DOI: 10.1016/S0415-6412(16)30084-4 Journal Club

18. Kloiber S, Musil R. Akupunktur bei psychiatrischen Erkrankungen - Literaturüberblick und Entwicklungsmöglichkeiten. Teil 2: Depressive Erkrankungen (unipolare Depression, schwangerschaftsassoziierte depressive Störungen, Poststroke Depression), Angststörungen. Deutsche Zeitschrift für Akupunktur 2016;59,1:6-11

19. Musil R, Kloiber S. Akupunktur bei psychiatrischen Erkrankungen- Literaturüberblick und Entwicklungsmöglichkeiten. Teil 1: Demenzerkrankungen, substanzbedingte Erkrankungen, Essstörungen, Persönlichkeitsstörungen, Aufmerksamkeitsdefizit-/Hyperaktivitätssyndrom. Deutsche Zeitschrift für Akupunktur 2016;59,1:7–13

20. Palm U, Musil R, Ienciu M, Jakovljevic M, Kapfhammer HP, Kasper S, Keck ME, Langguth B, Lanzenberger R, Meisenzahl E, Möller HJ, Müller N, Nedopil N, Sartorius N, Schöny W, Falkai P. The 26th Danube Symposium of Psychiatry: Psychiatry - ready for the future?
    Psychiatr Danub. 2016 Mar;28(1):95-6

21. Musil R. Weight gain as a consequence of treatment with antipsychotics - What do we know and what can we do?
    Die Psychiatrie 2015; 12: 262–268

22. Musil R, Krieger I. 1. DÄGfA-Symposium „Akupunktur und Psychiatrie“ überwindet Grenzen und setzt neue Akzente
    Deutsche Zeitschrift für Akupunktur 2015 Dec. (58) 1:48-49 DOI: 10.1016/S0415-6412(15)60020-0

23. Schennach R, Musil R, Möller HJ, Riedel M. Functional outcomes in schizophrenia: employment status as a metric of treatment outcome.
    Curr Psychiatry Rep. 2012 Jun;14(3):229-36. Review
    Impact Factor (2012): 2,711

24. Musil R. The safety, acceptability, and effectiveness of acupuncture as an adjunctive treatment for acute symptoms in bipolar disorder.
    Deutsche Zeitschrift für Akupunktur 2011 (54) 4:21-22 Journal Club

25. Riedel M, Musil R, Seemüller F, Spellmann I, Möller HJ, Schennach-Wolff R. Safety evaluation of zotepine for the treatment of schizophrenia.
    Expert Opin Drug Saf. 2010; Jul;9(4):659-66. Review
    Impact Factor (2010): 2,645

26. Riedel M, Spellmann I, Musil R, Seemüller F, Möller HJ, Schennach-Wolff R. Prädiktoren der Akutbehandlung in der Schizophrenie.
    Ärztliche Praxis Neurologie/Psychiatrie 02/2010

27. Bondy B, Spellmann I, Musil R, Zill P, Müller N, Möller HJ, Riedel M. Die Bedeutung der Pharmakogenetik für die antipsychotische Therapie.
    In „Schizophrenie - Zukunftsperspektiven in Klinik und Forschung“. Hrsg. Möller, Müller (2010) SpringerWienNewYork

28. Schwarz MJ, Musil R, Spellmann I, Opgen-Rhein M, Jurgeleit F, Sirch S, Sterz S, Zach J, Riedel M. Therapeutisches Drug-Monitoring neuerer atypischer Antipsychotika.
    In „Schizophrenie - Zukunftsperspektiven in Klinik und Forschung“. Hrsg. Möller, Müller (2010) SpringerWienNewYork

29. Riedel M, Seemüller F, Musil R, Spellmann I, Möller HJ, Schennach-Wolff R. Early Improvement and Its Predictive Validity in First-Episode Schizophrenia Patients.
    In “Handbook of Schizophrenia Spectrum Disorders, Volum III”. Hrsg. Ritsner, M.S. (2011) Springer Science+Business Media B.V.

30. Schennach-Wolff R, Seemüller F, Musil R, Spellmann I, Möller HJ, Riedel M. Suicidality and Outcome in Schizophrenia.
    In “Handbook of Schizophrenia Spectrum Disorders, Volum III”. Hrsg. Ritsner, M.S. (2011) Springer Science+Business Media B.V.

31. Schennach R, Musil R, Riedel M, Möller HJ. Current developments in the treatment of schizophrenia - a short review.
    Hospital Healthcare Europe: current developments in the treatment of schizophrenia, (2012)

32. Musil R. Praxisjahr für Mediziner im Ausland
    Deutsche Zeitschrift für Akupunktur 2010 Dec. (53) 1:72-72

33. Fleckenstein J, Musil R, Kracht R, Allmendinger B, Weißer S, Kloiber S, Trinczek K. Komplementärmedizin als Kommunikation zwischen Arzt und Mensch: - Erfahrungen von Studierenden der Medizin aus der DÄGfA Summer School of Acupuncture
    Deutsche Zeitschrift für Akupunktur 2009 Dec. (52) 4:4-5

34. Riedel M, Musil R, Spellmann I, Seemüller F and Möller HJ, (2008). Quetiapine XR – A new retarded Formulation in the Treatment of Schizophrenia.
    European Psychiatric Review 2008;

35. Riedel M, Schennach-Wolff R, Musil R, Seemüller F, Spellmann I. Atypische Antipsychotika – Wie fällt der Wirksamkeitsvergleich aus?
    DNP, DGPPN Sonderheft 2008

Kumulativer impact factor sonstige Beiträge, Übersichtsarbeiten und Buchbeiträge: 5,756

1. Cath DC, Hedderly T, Ludolph AG, Stern JS, Murphy T, Hartmann A, Czernecki V, Robertson MM, Martino D, Munchau A, Rizzo R; ESSTS Guidelines Group. European clinical guidelines for Tourette syndrome and other tic disorders. Part I: assessment.
   Eur Child Adolesc Psychiatry. 2011 Apr;20(4):155-71. Erratum in: Eur Child Adolesc Psychiatry. 2011 Jul;20(7):377.
   Impact Factor (2010): 1,622

2. Roessner V, Plessen KJ, Rothenberger A, Ludolph AG, Rizzo R, Skov L, Strand G, Stern JS, Termine C, Hoekstra PJ; ESSTS Guidelines Group. European clinical guidelines for Tourette
   syndrome and other tic disorders. Part II: pharmacological treatment.
   Eur Child Adolesc Psychiatry. 2011 Apr;20(4):173-96. Erratum in: Eur Child Adolesc Psychiatry. 2011 Jul;20(7):377.
   Impact Factor (2010): 1,622

3. Verdellen C, van de Griendt J, Hartmann A, Murphy T; ESSTS Guidelines Group. European clinical guidelines for Tourette syndrome and other tic disorders. Part III: behavioural and psychosocial interventions.
   Eur Child Adolesc Psychiatry. 2011 Apr;20(4):197-207. Erratum in: Eur Child Adolesc Psychiatry. 2011 Jul;20(7):377.
   Impact Factor (2010): 1,622

4. Müller-Vahl KR, Cath DC, Cavanna AE, Dehning S, Porta M, Robertson MM, Visser-Vandewalle V; ESSTS Guidelines Group. European clinical guidelines for Tourette syndrome and other tic disorders. Part IV: deep brain stimulation.
   Eur Child Adolesc Psychiatry. 2011 Apr;20(4):209-17. Erratum in: Eur Child Adolesc Psychiatry. 2011 Jul;20(7):377.
   Impact Factor (2010): 1,622

Kumulativer impact factor Leitlinien: 6,488

Anzahl Publikationen (ohne abstracts):
134 (36 Erst- oder Letztautorschaften, davon 15 bei Originalia)

Kumulativer Impact: 387,326
Recommendations: 206
h-index: 33 (ResearchGate)
h-index: 37 (GoogleScholar)
i10-index: 72
Citations (Research Gate): 4480
Research Interest Score: 2351
Reads: 27.741

Reviewertätigkeiten für Bioengineering; Bipolar Disorders; BMC Psychiatry; BMJ Open; children; CNS Drugs; CNS Spectrums; Depression and Anxiety; Deutsche Zeitschrift für Akupunktur; Drugs and Therapy Perspectives; eBio Medicine; European Archives of Psychiatry and Clinical Neurosciences; European Neuropsychopharmacology; European Psychiatry; Evidence-Based Complementary and Alternative Medicine; Expert Opinion on Drug Safety; Fortschritte der Neurologie & Psychiatrie; Frontiers in Psychiatry; Genetics and Molecular Biology; Journal of Affective Disorders; Journal of Clinical Psychiatry; Journal of Clinical Psychopharmacology; Journal of Clinical Psychiatry; Journal of Psychiatric Research; Neurology, Psychiatry and Brain Research; Neuropsychopharmacology; Neuroscience; Obesity Research & Clinical Practice; Pharmacogenomics; Pharmacopsychiatry; PLOS One; Psychiatric Genetics; Psychiatry Research; Psychoneuroendocrinology; Psychopharmacology; Psychotherapy and Psychosomatics; Schizophrenia; Translational Psychiatry; Veterinary Sciences; World Journal of Biological Psychiatry; Zeitschrift für Gerontologie und Geriatrie
2012-2015: Editorial Board BMC Psychiatry, Mood Disorders
2023-ongoing: Editorial Board Frontiers in Psychiatry, Section Psychopharmacology